We would love to hear your thoughts about our site and services, please take our survey here.
There are no other proven treatments. Nothing is that effective against it. We're no better than the mABs. Only thing to do no is to trade this one to try an recoup some money. It's going to be volatile for a while.
I have access to the paper. It's about the role of Interferon in modulating the bodies immune response and prolonging the survival of tissue grafts. Interferon seems to be a key signalling mechanism in the bodies immune response, so whilst this is an interesting paper it has nothing to do with treating viral infections.
Sorry Doc - the Chat was part of the channel but WAS started to be used when LSE went through a very flakey period and kept falling over. I know as I suggested we make use of the chat function and was the 1st person to say something on it to welcome people to it. Due to the continuous nature of it couldn't really keep up with it and work so used LSE as my main source of info until recently
Would also point out that the Reddit channel existed first and the chat came about when LSE fell over for the umpteenth time one week. There was no secret plan to create another group chat!
The difference with the chat to here is that it is one continuous stream (think whatsapp), so has a far lower posting volume to here as otherwise it would be difficult to keep discussions going. I will add that there is a fair amount of cross posting between LSE and Reddit and the only time I haven't seen something on here is where someone is posting correspondence (or detailed summaries of it) they have had with certain people (no, no one from Synairgen).
Looks like the other mAB on ACTIV-2 is now useless: https://www.biorxiv.org/content/10.1101/2022.02.07.479306v1
"The identification of the Omicron variant (B.1.1.529.1 or BA.1) of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in Botswana in November 20211 immediately raised alarms due to the sheer number of mutations in the spike glycoprotein that could lead to striking antibody evasion. We2 and others3-6 recently reported results in this Journal confirming such a concern. Continuing surveillance of Omicron evolution has since revealed the rise in prevalence of two sublineages, BA.1 with an R346K mutation (BA.1+R346K) and B.1.1.529.2 (BA.2), with the latter containing 8 unique spike mutations while lacking 13 spike mutations found in BA.1. We therefore extended our studies to include antigenic characterization of these new sublineages. Polyclonal sera from patients infected by wild-type SARS-CoV-2 or recipients of current mRNA vaccines showed a substantial loss in neutralizing activity against both BA.1+R346K and BA.2, with drops comparable to that already reported for BA.12,3,5,6. These findings indicate that these three sublineages of Omicron are antigenically equidistant from the wild-type SARS-CoV-2 and thus similarly threaten the efficacies of current vaccines. BA.2 also exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies tested, including S309 (sotrovimab)7, which had retained appreciable activity against BA.1 and BA.1+R346K2-4,6 . This new finding shows that no presently approved or authorized monoclonal antibody therapy could adequately cover all sublineages of the Omicron variant."
Very well said. And by too cheap you should be thinking anything less than £75. This is the lowest broker target should govs start stockpiling treatments, and quite frankly if results are good from P3 we should all be thinking about exit strategies and this route is in my planning.
Glad everyone's enjoyed this thread! For me at least, if you cut out the noise, then hidden within it has been a good debate on what the 90 day follow-up could mean. I think the conclusion is that the results RNS probably won't include 90 day data. The release of the P3 RNS may or may not be waiting for the 90 days to complete. The time to analyse primary end points (based on prior experience) just happens to fall quite closely to the 90th day of last patient dosed, so it could be good optics for Synairgen to spend as much time as possible on interpreting the results by not jeopardising the 90 day follow-up
And for clarity, headlined the thread as being about 90 days as this could be a reason for waiting as in they want to release the data as a whole package. However as has been pointed out it could be just to maintain the integrity of the 90 day data but without completing the analysis. Either way am still comfortable with timelines
I don't think 90 day data means mid summer, and I may well be wrong that they can release data in the next couple of weeks with it. Even if there is no 90 day data the rest of the post still stands.
Was watching Dragon's Den last night, and it occurred to me that the release of this RNS is akin to the biggest pitch that Synairgen can make. It's got to get across a USP and sufficiently convincing numbers (instead of ability to make a financial return the ability to meaningfully improve patient outcomes). If they are waiting for the 90 day data, then they could be trying to roll it all up into a knockout pitch with 3 USPs:
1. The best treatment for severe Covid, by an order of magnitude over the next competitor (if P2 results are replicated)
2. Not only variant agnostic, but virus agnostic, by focussing on boosting the body's own response rather than targeting the virus itself
3. The only proven treatment to reduce the prevalence of Long Covid
If it can do all three then the news outlets could be hailing this as the 1st available "Second Generation treatment" for Covid. All of these mABS getting labelled as 1st generation as they are virus targeted, and although quickly available have increasingly become obsolete. What a position to be in. In this context very happy to wait for another week or two.
31st January 2022
Valereum Plc
("Valereum" or the "Company")
$10 million Funding Facility with US led Syndicate
Valereum is pleased to announce that it has drawn US$3m from a new US$10m investment facility provided by a syndicate of institutional investors led by a US managed institutional investor. These funds will be used to advance Valereum's acquisition of the Gibraltar Stock Exchange ("GSX"). This will enable the previously announced strategy to be put in place.
Richard Poulden, Chairman of Valereum commented: "It is great to have international institutional support for our projects in Gibraltar."
This US$3m tranche has a six-month term (the "term"), after which the facility can be repaid or extended at Valereum's option.
Outstanding principal amounts may be converted into ordinary shares at £0.3682 during the term. After six months, if extended, conversion may occur at that price or, if lower, at a 5% discount to the then current 10 day lowest daily VWAP.
This drawing carries 663,302 two-year warrants at £0.3347.
The Directors of the Company accept responsibility for the contents of this announcement.
END
"Looking ahead, PwC says it expects larger companies that have been making divestments to start diversifying their portfolios into adjacent therapeutic areas. This year could see continued biotech acquisitions in the $5 billion to $15 billion range "as companies continue to make bets to fill potential gaps in their 2024 to 2026 pipelines," the firm predicts."
Taken from https://www.fiercepharma.com/special-report/top-10-biopharma-m-a-deals-2021